This is a working overview of prothymosin alpha, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-24. Anything still debated is marked as such rather than presented as settled.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual description varies by batch |
| Solubility | Freely soluble in water | Aqueous buffers are commonly used |
| Typical storage temperature | -20 °C or below for powder | Reconstituted liquid kept at 2-8 °C short term |
| Purity method | Reversed-phase HPLC | Value derived from peak area integration |
| Identity method | Mass spectrometry | Confirms mass and sequence integrity |
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
== Properties == Glyoxalase I requires bound metal ions for catalysis. The human enzyme and its counterparts in yeast (Saccharomyces cerevisiae) and Pseudomonas putida use divalent zinc, Zn2+. By contrast, the prokaryotic versions often use a nickel ion. The glyoxalase I found in eukaryotic trypanosomal parasites such as Leishmania major and Trypanosoma cruzi can also use nickel for activity, possibly reflecting an acquisition of their GLO1 gene by horizontal gene transfer. A property of glyoxalase I is its lack of specificity for the catalytic metal ion. Most enzymes bind one particular type of metal, and their catalytic activity depends on having bound that metal. For example, oxidoreductases often use a specific metal ion such as iron, manganese or copper and will fail to function if their preferred metal ion is replaced, due to differences in the redox potential; thus, the ferrous superoxide dismutase cannot function if its catalytic iron is replaced by manganese, and vice versa. By contrast, although human glyoxalase I prefers to use divalent zinc, it is able to function with many other divalent metals, including magnesium, manganese, cobalt, nickel and even calcium; however, the enzyme is inactive with the ferrous cation. Similarly, although the prokaryotic glyoxalase I prefers nickel, it is able to function with cobalt, manganese and cadmium; however, the enzyme is inert with bound zinc, due to a change in coordination geometry from octahedral to trigonal bipyramidal.
Setipiprant (INN; developmental code names ACT-129968, KYTH-105) is an investigational drug developed for the treatment of asthma and scalp hair loss. It was originally developed by Actelion and acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). The drug is being developed as a novel treatment for male pattern baldness by Allergan.
Chick-fil-A's business strategy involves a focus on a small menu and on customer service. While many fast food chains offer many dishes, Chick-fil-A's is focused on selling chicken sandwiches. The name's capital A is intended to indicate that their chicken is "grade A top quality". The company's emphasis on customer service is reported to have contributed to its success and growth in the United States. Chick-fil-A builds and owns its restaurants. Chick-fil-A franchisees need a US$10,000 initial investment. Franchisees are selected and trained, a process that can take months. Chick-fil-A grossed an average of $6.71 million per restaurant in 2022, despite opening only 6 days a week, the highest sales of all fast-food restaurants in the United States. (Raising Cane's was second with $5.44 million per restaurant average). In 2019, Chick-fil-A reported $11.3 billion in sales in the United States, behind only McDonald's with $40.4 billion in sales that year. To compete with Chick-fil-A, the fried chicken chain Popeyes, followed by others, introduced a fried chicken sandwich in 2019, a marketing trend known as the chicken sandwich wars.
Artificial bone can be created from ceramics such as calcium phosphates (e.g. hydroxyapatite and tricalcium phosphate), Bioglass and calcium sulfate; all of which are biologically active to different degrees depending on solubility in the physiological environment. These materials can be doped with growth factors, ions such as strontium or mixed with bone marrow aspirate to increase biological activity. Some authors believe this method is inferior to autogenous bone grafting; however, infection and rejection of the graft is much less of a risk, and the mechanical properties such as Young's modulus are comparable to bone. The presence of elements such as strontium can result in higher bone mineral density and enhanced osteoblast proliferation in vivo.
One example of a paper-based microfluidic device utilizing electrochemical detection has a dumbbell shape to isolate plasma from whole blood. The current from the hydrogen peroxide produced in the aforementioned catalytic cycle is measured and converted into concentration of glucose.
Sources: en.wikipedia.org
Stoolmiller AC, Horwitz AL, Dorfman A (1972). "Biosynthesis of the chondroitin sulfate proteoglycan. Purification and properties of xylosyltransferase". J. Biol. Chem. 247 (11): 3525–32. doi:10.1016/S0021-9258(19)45172-7. PMID 5030630. Gotting C, Kuhn J, Zahn R, Brinkmann T, Kleesiek K (2000). "Molecular cloning and expression of human UDP-d-Xylose:proteoglycan core protein beta-d-xylosyltransferase and its first isoform XT-II". J. Mol. Biol. 304 (4): 517–28. doi:10.1006/jmbi.2000.4261. PMID 11099377.
District Court judicial nominees who Kennedy believed were not qualified: Jeff Mateer, Brett Talley, and Matthew S. Petersen. The White House withdrew all three nominations. On December 13, 2017, during Petersen's confirmation hearing before the Senate Judiciary Committee, Kennedy asked Petersen about basic legal procedure, whether he knew what the Daubert standard was and what a motion in limine was. Petersen struggled to answer. Kennedy also voted against the nomination of Gregory G. Katsas to the D.C. Circuit, but Katsas was confirmed. On April 7, 2017, Kennedy voted to confirm Neil Gorsuch to the United States Supreme Court. Kennedy participated in Gorsuch's confirmation as a member of the Judiciary Committee. During the confirmation process, Kennedy said, “Neil Gorsuch is obviously very well-qualified based on his education and background, but I want to know what’s in his heart. I want to know what he thinks about past Supreme Court decisions and how the justices reached those decisions. I want to know whether he thinks personal preferences have a role in the judicial decision-making. I want to know if he knows the name of the person who cleans his office. Also, I'm rather fond of the U.S. Constitution, and I want to make sure he is, too." On October 6, 2018, Kennedy voted to confirm Brett Kavanaugh to the Supreme Court. As a member of the Judiciary Committee, Kennedy participated in Kavanaugh's contentious nomination hearing after Christine Blasey Ford accused Kavanaugh of sexual assault.
These initially involved groups of soldiers that were inserted by helicopter, and were later expanded with paratroopers. The Rhodesian Light Infantry often provided the soldiers for fireforce teams. A key element of the Selous Scouts' methods was 'turning' captured insurgents to join the Rhodesian security forces. This was normally attempted shortly after insurgents were captured, with them being both threatened and offered incentives. The captured insurgent was usually approached by a former insurgent. In the resulting conversation, the former insurgent emphasised the hardships insurgents were experiencing and that those who were captured faced the death penalty under the Law and Order (Maintenance) Act. This legislation imposed severe penalties for people found to be members of subversive organisations, including the death penalty or long prison terms. The captured insurgent was also offered a lump sum payment as well as a soldier's salary if they agreed to fight for the Rhodesian government. If an insurgent agreed to be 'turned' and passed further vetting, they were assigned to a Selous Scout team and operated in regions in which they would not be recognised. Where possible, their family was housed on a Selous Scouts base. Only a small number of 'turned' insurgents ever deserted or betrayed the unit. Some of the prisoners captured by the Selous Scouts who refused to be 'turned' were killed. One of the tactics used by the Selous Scouts was to violate local customs while posing as insurgents with the goal of reducing support for the actual insurgents.
Chestnut is a hair coat color of horses consisting of a reddish-to-brown coat with a mane and tail the same or lighter in color than the coat. Chestnut is characterized by the absolute absence of true black hairs. It is one of the most common horse coat colors, seen in almost every breed of horse. Chestnut is a very common coat color but the wide range of shades can cause confusion. The lightest chestnuts may be mistaken for palominos, while the darkest shades can be so dark they appear black. Chestnuts have dark brown eyes and black skin, and typically are some shade of red or reddish brown. The mane, tail, and legs may be lighter or darker than the body coat, but unlike the bay they are never truly black. Like any other color of horse, chestnuts may have pink skin with white hair where there are white markings, and if such white markings include one or both eyes, the eyes may be blue. Chestnut foals may be born with pinkish skin, which darkens shortly afterwards. Chestnut is produced by a recessive gene. Unlike many coat colors, chestnut can be true-breeding; that is, assuming they carry no recessive modifiers like pearl or mushroom, the mating between two chestnuts will produce chestnut offspring every time. This can be seen in breeds such as the Suffolk Punch and Haflinger, which are exclusively chestnut. Other breeds including the American Belgian Draft and Budyonny are predominantly chestnut. However, a chestnut horse need not have two chestnut parents.
Sources: en.wikipedia.org
Cold storage slows the chemical degradation reactions that occur in solution. Lyophilized powder is more stable than reconstituted liquid and tolerates longer storage periods. Repeated temperature cycling should still be avoided because it can drive aggregation and loss of material.
Mass spectrometry is the standard confirmation of molecular mass and acetylation state. Chromatography establishes purity but does not identify the molecule on its own. The two techniques are normally applied together during verification.
No, because the reported value reflects the detection method and wavelength used, which vary between laboratories. A number stated without method details cannot be compared directly with another supplier's figure. Requesting the chromatogram and the method conditions is a common way to interpret it.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.